Declan Doogan
Adjunct Professor of Psychiatry @ University College Cork
Douglas, Isle of Man
Declan Doogan is a seed investor at University College Cork in Douglas focused on Biopharma and Therapeutics. Declan Doogan has over 30 years of industry experience in both major pharma and biotech.He was the Senior Vice-President and Head of Worldwide Development at Pfizer, where many multibillion dollar programs were delivered (e.g., Viagra, Lipitor and Zoloft). He has held a number of executive positions in Pfizer in the US, the UK and Japan. Sinceleaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin (AMRN: Nasdaq), transforming it from a failing Neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He has also been Chief Medical Officer for Prometheus Laboratories, a molecular diagnostics company in San Diego. Declan is also an investor in emerging biotechnology and technology companies. He holds a number of Board appointments, principally in pharma companies, and has also held professorships positions at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo).Declan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the UK.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Declan Doogan invests in
Stages Declan Doogan invests in
Countries Declan Doogan invests in
Investment Focus
Industry
- Biopharma 2 (67%)
- Therapeutics 2 (67%)
- Biotechnology 2 (67%)
- Health Care 1 (33%)
- Pharmaceutical 1 (33%)
Stage
- Seed 1 (33%)
- Series A 1 (33%)
- Venture - Series Unknown 1 (33%)
Country
- United States 1 (33%)
- United Kingdom 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Causeway Therapeutics
|
A bio pharmaceutical spin out emerging from the University of Glasgow, working in the orthobiologic therapeutic space. Intellectual property has been generated via academic research demonstrating a proven mechanistic reasoning for the use of a microRNA therapy in the treatment of tendinopathies. | $10.5M / Venture - Series Unknown / Feb 22, 2023 | |
|
Causeway Therapeutics
|
A bio pharmaceutical spin out emerging from the University of Glasgow, working in the orthobiologic therapeutic space. Intellectual property has been generated via academic research demonstrating a proven mechanistic reasoning for the use of a microRNA therapy in the treatment of tendinopathies. | $1.3M / Seed / Aug 03, 2017 | |
Intensity Therapeutics
|
Intensity Therapeutics, Inc., a biopharmaceutical company, provides chemotherapy treatments for cancer patients. It engages in the direct intratumoral injection of novel pharmaceutical formulations for cancer administration. Intensity Therapeutics, Inc. was incorporated in 2012 and is based in Norwalk, Connecticut. | $10M / Series A / Jun 28, 2016 |
Co-Investors
About University College Cork
University College Cork is a higher education institution. The new college's location was dramatic and picturesque, perched on the edge of a limestone bluff overlooking. At the turn of the twentieth century, it was clear that higher education in Ireland required a new arrangement to allow for the next stages of development.
University College Cork Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alan Duncan
Associate Faculty, Business Information Systems
|
|||
|
Declan Doogan
Adjunct Professor of Psychiatry
|
|||
Eugene Crehan
External Examiner UCC - Higher Diploma in Leadership Development
|
|||
John Cryan
Professor & Chair, Dept. Anatomy & Neuroscience; Vice President for Research & Innovation
|
|||
Klaas-Jan Stol
Lecturer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Declan Doogan invest in?
Declan Doogan invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Declan Doogan last invest?
The most recent investment recorded for Declan Doogan closed in Feb 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
